Atossa Genetics (NASDAQ:ATOS) Issues Quarterly Earnings Results

Atossa Genetics (NASDAQ:ATOS) issued its quarterly earnings data on Friday. The company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.09, FiscalAI reports.

Atossa Genetics Price Performance

Shares of ATOS stock traded down $0.06 during midday trading on Friday, hitting $2.36. The company had a trading volume of 77,520 shares, compared to its average volume of 66,253. The stock has a market cap of $20.32 million, a price-to-earnings ratio of -0.74 and a beta of 1.29. The company’s 50 day simple moving average is $2.62 and its 200 day simple moving average is $4.51. Atossa Genetics has a 52-week low of $1.70 and a 52-week high of $19.35.

Institutional Investors Weigh In On Atossa Genetics

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after buying an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Atossa Genetics in the second quarter valued at about $2,468,000. Renaissance Technologies LLC boosted its holdings in shares of Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after acquiring an additional 514,175 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Atossa Genetics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after acquiring an additional 9,627 shares during the period. Finally, State Street Corp increased its stake in shares of Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares during the period. 12.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ATOS. Rodman & Renshaw began coverage on shares of Atossa Genetics in a report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Finally, Ascendiant Capital Markets lowered their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $20.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.